EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions

N N Ngcobo iD

Journal of Evaluation in Clinical Practice · 2025-10 · 31 (7)

DOI: 10.1111/jep.70283 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Evaluation in Clinical Practice, online erschienen am 30.09.2025. Verfasst von N N Ngcobo. Beteiligte Einrichtung: Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Polypharmacy, Multimorbidity, Drug-Related Side Effects and Adverse Reactions, Medication Errors. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacological therapy in older persons is inherently complex due to the interplay of age‐related physiological changes, multimorbidity, and polypharmacy. These factors increase the vulnerability of elderly patients to drug interactions and adverse drug reactions.

Aim

This review aims to examine the mechanisms, causes, and consequences of drug interactions in older persons, and to highlight strategies to optimise pharmacological therapy in this population.

Methods

A narrative review of current literature was conducted, focusing on studies that address age‐related pharmacological changes, multimorbidity, polypharmacy, and drug–drug interactions in elderly patients.

Results

Findings from the literature indicate that drug interactions represent one of the most preventable medical errors in older persons' pharmacotherapy. The global scale of this problem highlights the need for increased awareness and collaborative approaches among healthcare providers.

Conclusion

Improving the quality of pharmacotherapy in older adults requires a concerted effort to prevent drug interactions, optimise prescribing practices, and ensure patient safety. Collaborative interventions can reduce adverse drug events and enhance therapeutic outcomes in elderly care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolypharmacyMultimorbidityDrug-Related Side Effects and Adverse ReactionsMedication ErrorsHumansDrug InteractionsAgedAged, 80 and over

Stichwörter der Autor:innen

elderly personsmultimorbiditypharmacological interactionspharmacotherapypolypharmacy

Autor:innen und Institutionen

  • Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

ORCID-Profile: N N Ngcobo

Zitieren

APA

Ngcobo, N. N. (2025). Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions. Journal of Evaluation in Clinical Practice, 31(7). https://doi.org/10.1111/jep.70283

Vancouver

Ngcobo NN. Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions. Journal of Evaluation in Clinical Practice. 2025;31(7). doi:10.1111/jep.70283

BibTeX
@article{Ngcobo2025,
  author = {Ngcobo, N N},
  title = {Silent Dangers in Elderly Pharmacotherapy: The Interplay of Polypharmacy, Multimorbidity, and Drug Interactions},
  journal = {Journal of Evaluation in Clinical Practice},
  year = {2025},
  volume = {31},
  number = {7},
  doi = {10.1111/jep.70283}
}
Kostenlos starten →